CTOs on the Move

Xenocor

www.xenocor.com

 
Bringing to market revolutionary laparoscopic technologies which extend the benefits of minimally invasive surgery to hundreds of millions of people worldwide.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.xenocor.com
  • 630, Komas Drive
    Salt Lake City, UT USA 84108
  • Phone: 844.936.6267

Executives

Name Title Contact Details

Similar Companies

Prescription Corporation of America

Prescription Corporation of America is a Denville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vigil Neuroscience

Vigil Neuroscience is the world`s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain`s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.

Immuno Vaccine

Immuno Vaccine is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DPT Laboratories

DPT is a contract development and manufacturing organization specializing in semi-solid and liquid dosage forms. Recognized globally for technical expertise and virtually unlimited manufacturing capabilities, DPT is the industry source for fully

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.